Literature DB >> 12481549

Endocannabinoids and their actions.

Mauro Maccarrone1, Alessandro Finazzi-Agrò.   

Abstract

Endocannabinoids are a new class of lipid mediators, which includes amides and esters of long-chain polyunsaturated fatty acids. Anandamide (I) and 2-arachidonoylglycerol (II) are the main endogenous agonists of cannabinoid receptors, able to mimic several pharmacological effects of delta 9-tetrahydrocannabinol (III), the active principle of Cannabis sativa preparations such as hashish and marijuana. The pathways leading to the synthesis and release of anandamide and 2-arachidonoylglycerol from neuronal and nonneuronal cells are rather uncertain. Instead, evidence has accumulated showing that the activity of these compounds at their specific receptors is limited by cellular uptake through a specific membrane transporter, followed by intracellular degradation by a fatty acid amide hydrolase. Here, the endocannabinoids and the endocannabinoid-like compounds most relevant for human physiology will be discussed, along with the synthetic and degradative pathways of anandamide and 2-arachidonoylglycerol and their molecular targets on the cell surface. The main actions of the endocannabinoids in human cells and tissues will also be reviewed, focusing on the activities most recently discovered in the central nervous system and in the periphery.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12481549     DOI: 10.1016/s0083-6729(02)65066-6

Source DB:  PubMed          Journal:  Vitam Horm        ISSN: 0083-6729            Impact factor:   3.421


  21 in total

1.  Levels of N-acylethanolamines in human tumors: in search of reliable data.

Authors:  Mauro Maccarrone; Filomena Fezza; Alessandro Finazzi-Agrò
Journal:  Lipids       Date:  2004-02       Impact factor: 1.880

Review 2.  [The endogenous cannabinoid system. Therapeutic implications for neurologic and psychiatric disorders].

Authors:  U Schneider; J Seifert; M Karst; J Schlimme; K Cimander; K R Müller-Vahl
Journal:  Nervenarzt       Date:  2005-09       Impact factor: 1.214

3.  Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes.

Authors:  Jessica P Alexander; Benjamin F Cravatt
Journal:  Chem Biol       Date:  2005-11

Review 4.  Cannabinoids and cancer: pros and cons of an antitumour strategy.

Authors:  Maurizio Bifulco; Chiara Laezza; Simona Pisanti; Patrizia Gazzerro
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

Review 5.  Physiological and molecular determinants of embryo implantation.

Authors:  Shuang Zhang; Haiyan Lin; Shuangbo Kong; Shumin Wang; Hongmei Wang; Haibin Wang; D Randall Armant
Journal:  Mol Aspects Med       Date:  2013-01-02

6.  Structural equation modeling of food craving across the menstrual cycle using behavioral, neuroendocrine, and metabolic factors.

Authors:  Sridevi Krishnan; Karan Agrawal; Rebecca R Tryon; Lucas C Welch; William F Horn; John W Newman; Nancy L Keim
Journal:  Physiol Behav       Date:  2018-07-18

Review 7.  The promise and dilemma of cannabinoid therapy: lessons from animal studies of bone disease.

Authors:  Aymen I Idris
Journal:  Bonekey Rep       Date:  2012-11-21

8.  Endocannabinoids anandamide and its cannabinoid receptors in liver fibrosis after murine schistosomiasis.

Authors:  Hongyan Liu; Xiao Gao; Ruixian Duan; Qiao Yang; Yaowen Zhang; Yongwei Cheng; Yan Guo; Wangxian Tang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-04-28

9.  Impact of embedded endocannabinoids and their oxygenation by lipoxygenase on membrane properties.

Authors:  Enrico Dainese; Annalaura Sabatucci; Clotilde B Angelucci; Daniela Barsacchi; Marco Chiarini; Mauro Maccarrone
Journal:  ACS Chem Neurosci       Date:  2012-02-24       Impact factor: 4.418

10.  Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism.

Authors:  Y Sun; S P H Alexander; M J Garle; C L Gibson; K Hewitt; S P Murphy; D A Kendall; A J Bennett
Journal:  Br J Pharmacol       Date:  2007-10-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.